Matthew Gormley Selected Research

ublituximab

1/2021	A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
1/2019	B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew Gormley Research Topics

Disease

3	Multiple Sclerosis 10/2021 - 01/2019
3	Neoplasms (Cancer) 01/2020 - 04/2012
2	Pre-Eclampsia (Preeclampsia) 01/2017 - 01/2009
2	Infections 05/2015 - 11/2011
1	Down Syndrome (Down's Syndrome) 01/2020
1	Pregnancy Complications 01/2016
1	Breast Neoplasms (Breast Cancer) 04/2012

Drug/Important Bio-Agent (IBA)

2	ublituximabIBA 01/2021 - 01/2019
2	RNA (Ribonucleic Acid)IBA 01/2017 - 01/2016
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 04/2012
1	Monoclonal AntibodiesIBA 01/2021
1	Caspase 2IBA 01/2020
1	Guanine Nucleotide Exchange Factors (Guanine Nucleotide Exchange Factor)IBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	Long Noncoding RNAIBA 01/2017
1	Small Nucleolar RNA (snoRNA)IBA 01/2017
1	Blood Group Antigens (Blood Groups)IBA 01/2017
1	Core Binding Factor Alpha 2 SubunitIBA 01/2016
1	Viral ProteinsIBA 05/2015
1	VaccinesIBA 05/2015
1	Conditioned Culture MediaIBA 04/2012
1	Glycoproteins (Glycoprotein)IBA 04/2012
1	Phenobarbital (Luminal)FDA Link 04/2012
1	LectinsIBA 04/2012
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2009
1	Immunoglobulins (Immunoglobulin)IBA 01/2009

Therapy/Procedure

1	Therapeutics 10/2021
1	Lasers (Laser) 01/2017
1	Transplantation 11/2011